Cancer – ADVL1615: Phase 1 Study of Pevonedistat, a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
Condition or Therapy:
Lymphoma, solid tumors
Cancer and Blood Disorders
Study Number: ADVL1615
What is the goal of this study?
Researchers want to determine the appropriate dosage of pevonedistat that should be given with irinotecan and temozolomide in treating patients with solid tumors or lymphoma that have come back after a period of improvement of that do not respond to treatment.
Who can join the study?
This study may be a good fit for children and young adults who:
- are 6 months to 21 years old, and
- have recurrent or refractory tumors including CNS and lymphoma.
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.